Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof

Egypt Nanotechnologies Center (egnc)

Graphene nanomesh based charge sensor


Date/App# patent app List of recent Receptor-related patents
08/20/15
20150234343 
 Image forming apparatus patent thumbnailImage forming apparatus
Provided is an image forming apparatus comprising a photoreceptor having a protective layer containing a crosslinked polymer as a surface layer, wherein, along with the rotation direction of the photoreceptor in the external area of the rotating photoreceptor, a lubricant supplying part that supplies lubricant onto the surface of the photoreceptor, a charging part that charges the surface of the photoreceptor by a charging roller, an exposure part that exposes the charged photoreceptor by the charging part, a developing part that supplies toner to the exposed photoreceptor by the exposure part to form a toner image, a transfer part that transfers the toner image formed on the photoreceptor, a cleaning part that removes the toner remained on the surface of the photoreceptor and a lubricant removing part that removes the lubricant adhered on the surface of the photoreceptor are sequentially disposed.. .

08/20/15
20150233927 
 Identifying taxane sensitivity in prostate cancer patients patent thumbnailIdentifying taxane sensitivity in prostate cancer patients
The invention relates to detection and/or treatment of a subset of prostate cancer patients who may benefit from taxane treatment. The method comprises testing whether an androgen receptor (ar) splice variant is present in a test sample obtained from the patient, wherein the androgen receptor variant can be arv5,6,7 or arv7, or a combination thereof..
University Of Washington


08/20/15
20150233925 
 Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof patent thumbnailAssays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof
Described herein are assays and complementary cell culture based tests, and uses thereof for determining agonists or antagonists of na/k-atpase/src complex, and methods of treatment therewith.. .
The University Of Toledo


08/20/15
20150233900 
 Graphene nanomesh based charge sensor patent thumbnailGraphene nanomesh based charge sensor
A graphene nanomesh based charge sensor and method for producing a graphene nanomesh based charge sensor. The method includes generating multiple holes in graphene to create a graphene nanomesh with a patterned array of multiple holes; passivating an edge of each of the multiple holes of the graphene nanomesh to allow for functionalization of the graphene nanomesh; and functionalizing the passivated edge of each of the multiple holes of the graphene nanomesh with a chemical compound that facilitates chemical binding of a receptor of a target molecule to the edge of one or more of the multiple holes, wherein the receptor is a molecule that chemically binds to the target molecule, irrespective of the size of the target molecule..
Egypt Nanotechnologies Center (egnc)


08/20/15
20150232940 
 Methods and compositions relating to diagnosing and treating receptor tyrosine kinase related cancers patent thumbnailMethods and compositions relating to diagnosing and treating receptor tyrosine kinase related cancers
Disclosed are methods and compositions for detecting the presence of a cancer in a subject and assessing the efficacy of treatments for the same. The disclosed method use reverse transcription polymerase chain reaction (rt-pcr), real time polymerase chain reaction, and multiplex polymerase chain reaction techniques to detect fusions, over-expression, truncation, and nucleic acid variation of ret and depdc1 in cancers..
Insight Genetics, Inc


08/20/15
20150232876 
 Use of a receptor kinase having lysm motifs in order to improve the response of plants to lipochitooligosaccharides patent thumbnailUse of a receptor kinase having lysm motifs in order to improve the response of plants to lipochitooligosaccharides
The invention relates to improving the response of a plant to lipochitooligosaccharidic nod and myc-lco factors, by means of the expression, in the plant, of a polypeptide which has a sequence homology with the extracellular domain of the lysm-motif-containing receptor kinase lyr3 in medicago truncatula and which is capable of binding to lipochitooligosaccharides with an increased affinity.. .
Universite Paul Sabatier (toulouse Iii)


08/20/15
20150232850 
 Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) patent thumbnailTreatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of insulin receptor substrate 2 (irs2) polynucleotides, in particular, by targeting natural antisense polynucleotides of insulin receptor substrate 2 (irs2) polyneucleotides and transcription factor e3 (tfe3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of irs2..
Curna, Inc.


08/20/15
20150232572 
 Combination treatment of cancer patent thumbnailCombination treatment of cancer
The present invention provides mt4-mmp inhibitor and egfr inhibitor for use in the treatment of cancer, wherein said mt4-mmp inhibitor and egfr inhibitor are different from each other. Mt4-mmp (mmp-17) is a glycosylphosphatidyl inositol (gpi) anchored mmp produced by cancer cells that promotes tumor vascularization and metastases.
UniversitÉ De LiÈge


08/20/15
20150232565 
 Modulation of activity of neurotrophins patent thumbnailModulation of activity of neurotrophins
The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (ngf), brain derived neurotrophic factor (bdnf), neurotrophin-3, and neurotrophin-4 (nt-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the vps10p-domain receptor family or modulating the expression of a receptor of the vps10p-domain receptor family.
H Lundbeck A/s


08/20/15
20150232564 
 Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor patent thumbnailRegulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
A method of reducing il-4 and/or il-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of il-3, il-5 and gm-csf to the βc common chain to thereby reduce the il-4 and/or il-13 levels.. .
Newcastle Innovation Ltd.


08/20/15
20150232563 

Novel mutated humanized 12g4 antibodies and the fragments thereof against the human anti-mullerian hormone receptor type ii


Novel mutated humanized 12g4 antibodies, and fragments thereof, directed against the anti-müllerian hormone type ii receptor.. .
I.n.s.e.r.m. (institut National De La Sante Et De La Recherche Medicale)


08/20/15
20150232562 

Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors


The present invention relates to amino acid sequences and nanobodies that are directed against epidermal growth factor receptor 2 (her2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.. .
Ablynx N.v.


08/20/15
20150232557 

Cd3 binding polypeptides


The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with cd3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scfvs, fabs, di-scfvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments.
Emergent Product Development Seattle Llc


08/20/15
20150232555 

Antibodies to human programmed death receptor pd-1


Antibodies which block binding of hpd-1 to hpd-l1 or hpd-l2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the pd-1 pathway is also disclosed..
Merck Sharp & Dohme B.v.


08/20/15
20150232554 

Frizzled-binding agents and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified.
Oncomed Pharmaceuticals, Inc.


08/20/15
20150232547 

Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins


The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble fibroblast growth factor receptor 1 (fgfr1) fusion protein such as an extracellular domain of an fgfr1 polypeptide linked to an fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight.
Five Prime Therapeutics, Inc.


08/20/15
20150232546 

Anti-pdgf-c antibodies


The invention relates to antibodies binding to the pdgf-c antigen and capable of inhibiting binding of pdgf-c to the pdgfrα receptor and of inhibiting pdgfrα activation by pdgf-c. Applications of such antibodies are also disclosed.
Thrombogenics Nv


08/20/15
20150232545 

Human antibodies to human delta like ligand 4


The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.


08/20/15
20150232531 

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof


The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence seq id no: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence seq id no: 1 or seq id no: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease..
UniversitÉ De Lorraine


08/20/15
20150232529 

High affinity tcr proteins and methods


T cell receptors (tcrs) that have higher affinity for a ligand than wild type tcrs are provided. These high affinity tcrs are formed by mutagenizing a t cell receptor protein coding sequence to generate a variegated population of mutants of the t cell receptor protein coding sequence; transforming the t cell receptor mutant coding sequence into yeast cells; inducing expression of the t cell receptor mutant coding sequence on the surface of yeast cells; and selecting those cells expressing t cell receptor mutants that have higher affinity for the peptide/mhc ligand than the wild type t cell receptor protein.
The Board Of Trustees Of The University Of Illinois


08/20/15
20150232512 

Synthetic peptide for adjusting balance between presence of type 1 tnf receptor and type 2 tnf receptor and use thereof


Provided is a method for adjusting the balance of tnf-r1 and tnf-r2 in cells present at a target organ, tissue or site. In the adjustment method provided, when increasing the relative presence of tnf-r2 compared to the presence of tnf-r1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of at a tnf-r1 signal peptide motif or a modified amino acid sequence thereof; and when decreasing the relative presence of tnf-r2 compared to the presence of tnf-r1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of a tnf-r2 signal peptide motif or a modified amino acid sequence thereof..
Toagosei Co., Ltd.


08/20/15
20150232492 

Heterobicyclic sphingosine 1-phosphate analogs


Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors..
Biogen Idec Ma Inc.


08/20/15
20150232491 

Prodrugs of 1,4-benzodiazepinone compounds


Disclosed are compounds of formula (i) and salts thereof, wherein: a) r1 is h or ch3, and r2 is ry; or b) r1 is rx and r2 is h; wherein rx and ry are disclosed herein. Also disclosed are methods of using such compounds to inhibit the notch receptor, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company


08/20/15
20150232485 

Multi-sensor array compound and methods of use thereof


The present invention is directed to a multi-sensor array compound including at least three chromophores, at least one receptor and an anchor. Contacting the compound of this invention with an analyte (such as carbohydrate) forms a complex with unique optical signature.
Yeda Research And Development Co. Ltd.


08/20/15
20150232478 

Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes


[wherein all symbols represent the same meanings as those described in the description] a salt thereof, an n-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction..

08/20/15
20150232475 

Nicotinic acetylcholine receptor agonists


The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula i. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as alzheimer's disease, schizophrenia, myasthenia gravis, tourette's syndrome, parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


08/20/15
20150232473 

Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma


Novel methods of treating inflammation and airway constriction using gabaergic compounds with reduced benzo-diazepine-like cns activity are provided. Novel compounds which selectively target alpha-4 and alpha-5 gabaa receptors and methods of using those compounds to treat bronchoconstriction and inflammation are provided herein..
Uwm Research Foundation, Inc.


08/20/15
20150232471 

Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders


And their use in therapeutic treatments.. .

08/20/15
20150232468 

Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells


Provided are: composition and methods for: treating aging or an age-related condition, symptom or disease; stimulating hair growth, regrowth or pigmentation (or preventing hair loss); for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of the disclosed cbp/catenin (e.g., cbp/b-catenin) antagonist compositions, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population.
University Of Southern California


08/20/15
20150232448 

6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones


A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones have been synthesized. The compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent d2 receptor antagonist and 5-ht1a receptor agonist properties.
King Fahd University Of Petroleum And Minerals


08/20/15
20150232443 

Bicyclic aza compounds as muscarinic m1 receptor agonists


This invention relates to compounds (formula (1)) that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
Heptares Therapeutics Limited


08/20/15
20150232442 

6-substituted phenoxychroman carboxylic acid derivatives


In which a1, a2, w, l, g, r7a, r7b, r8, r9 and r10 have the meanings given in the specification, which are dp2 receptor modulators useful in the treatment of immunologic diseases.. .

08/20/15
20150232435 

Urea and amide derivatives of aminoalkylpiperazines and use thereof


Provided are compounds represented by the formula: with y, ri, and r2 being defined in the present disclosure; pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition capable of treatment with a partial agonist or antagonist of the dopamine d2/d3 receptors and are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders.
Southern Research Institute


08/20/15
20150231391 

Apparatus for baroreceptor stimulation therapy


A medical apparatus comprising an implantable lead and a stylet configured for stimulation of a target region of a patient's nervous system is described. The lead includes a generally tubular lead body, a conductor, and an electrode assembly.
Cardiac Pacemakers, Inc.


08/20/15
20150231285 

Radiolabeled active targeting pharmaceutical composition and the use thereof


The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof.
National Yang-ming University


08/20/15
20150231251 

Compositions and methods for topical delivery of prostaglandins to subcutaneous fat


Described herein are compositions comprising a prostaglandin fp receptor agonist (pfpra) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the pfpra compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin.
Topokine Therapeutics, Inc.


08/20/15
20150231221 

Immunogenic compositions comprising progastrin and uses thereof


The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin ii, or both.
Board Of Regents, The University Of Texas System


08/20/15
20150231220 

Epitopes of epidermal growth factor receptor surface antigen and use thereof


The present invention relates to epitopes of the epidermal growth factor receptor (egfr) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (egf).
Green Cross Corporation


08/20/15
20150231213 

Nutritional compositions containing a prebiotic and lactoferrin and uses thereof


Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides..
Mead Johnson Nutrition Company


08/20/15
20150231210 

Pharmaceutical composition for treating a metabolic syndrome


The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Sanofi


08/20/15
20150231206 

Variant activin receptor polypeptides and uses thereof


The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
Amgen Inc.


08/20/15
20150231202 

High affinity ny-eso t cell receptors


The present invention provides t cell receptors (tcrs) having the property of binding to sllmwitqc-hla-a*0201, the sllmwitqc seq no:126 peptide being derived from the ny-eso-1 protein which is expressed by a range of tumour cells. The tcrs have a kd for the said peptide-hla complex of less than or equal to 1 μm and/or have an off-rate (koff) of 1×10−3 s−1 or slower..
Adaptimmune Limited


08/20/15
20150231158 

Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators


The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
Allergan, Inc.


08/20/15
20150231153 

Fulvestrant formulations


The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject..
Fresenius Kabi Usa, Llc


08/20/15
20150231152 

Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds


Disclosed are compounds of formula (i): (formula (i)) wherein: r1 is —ch2ch2cf3; r2 is —ch2ch2ch2f, —ch2cf2ch3, —ch2ch2cf3, —ch2ch(ch3)cf3, —ch2ch2cf2ch3, (formulae (ii), (iii), (iv), (v) or (vi): r3 is h or —ch3; ring a is phenyl or pyridinyl; and rx, ry, ra, rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the notch receptor, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company


08/20/15
20150231151 

Compositions and methods for the treatment of neurodegenerative diseases


In some embodiments, the present disclosure pertains to a composition for modulating the expression of at least one gene associated with neuronal cell survival or stability. In some embodiments, the present disclosure provides for compositions for the treatment of neurodegenerative diseases comprising one or more phosphate complexes of platinum of the formulas i, ii, iii and iv as set forth in fig.
University Of Houston System


08/20/15
20150231143 

Heteroaryl derivatives as alpha7 nachr modulators


Wherein z, m and r1-r6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as alzheimer's disease, mild cognitive impairment, senile dementia, and the like..

08/20/15
20150231141 

Novel compounds as cannabinoid receptor ligands and uses thereof


Wherein r1, r2, r3, r4, and l2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.. .

08/20/15
20150231127 

Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof


Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of m1, m2, m3, m4, m5) and for anesthetizing a subject include a bitopic muscarinic antagonist or agonist. A bitopic muscarinic antagonist named jb-d4 was discovered.
Barry University, Inc.


08/20/15
20150231121 

Positive allosteric modulators of nicotinic acetylcholine receptor


The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (pams) of the nicotinic acetylcholine α7 receptor..
H. Lundbeck A/s


08/20/15
20150231114 

3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors


(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds, are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.

08/20/15
20150231096 

Combination therapies using hdac inhibitors


The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (hdac) inhibitor, such as pxd-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (egfr) inhibitor, such as tarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.. .
Curagen Corporation


08/20/15
20150231052 

Mesenchymal stem cell extract and its use


A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (bmp-7), stromal cell-derived factor-1 (sdf-1), vascular endothelial growth factor (vegf), c-x-c chemokine receptor type-4 (cxcr4), brain-derived neurotrophic factor (bdnf), and/or interleukin-17 (il-17), and wherein the extract is especially suitable for repairing skin aging.. .
Gwo Xi Stem Cell Applied Technology Co., Ltd.


08/13/15
20150226750 

Nrip as a biomarker of abnormal function of motor neurons


The present invention provides a method for evaluating physiological state of motor neurons in a subject. The method comprises detecting an expression level of a nuclear receptor interaction protein (nrip) in a biological sample from the subject; and comparing the expression level of the nrip to a control value for nrip; wherein detecting a decrease of the expression level of the nrip in the biological sample from the subject as compared to the control value for nrip indicates an abnormal function of the motor neurons of the subject.
National Taiwan University


08/13/15
20150225838 

Directed surface functionalization on selected surface areas of topographical features with nanometer resolution


A method for making a single molecule receptor in a nanopore structure includes depositing a material by a physical vapor deposition (pvd) technique onto a selected interior surface of a nanochannel and functionalizing a surface of the material with a chemical compound having at least two functional groups. The material forms a patch having a diameter of about 3 to about 10,000 nanometers (nm).
International Business Machines Corporation


08/13/15
20150225790 

Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist


The invention describes a method for identifying subjects with an increased likelihood of responding to treatments that modulate chemokine or chemokine receptor activity by measuring the change in expression of immune mediated genes.. .
Bristol-myers Squibb Company


08/13/15
20150225699 

Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna


The nuclear reprogramming of somatic cells with mrna encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of pkr, of toll-like receptors, e.g.
The Board Of Trustees Of The Leland Stanford Junior University


08/13/15
20150225695 

Method of obtaining chicken embryonic stem cells


The present invention concerns a method of culturing embryonic stem (es) cells of avian, comprising the steps of: a) suspending es cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (igf-1) and ciliary neurotrophic factor (cntf); and animal serum; and optionally, at least one growth factors selected in the group comprising interleukin 6 (ii-6), interleukin 6 receptor (ii-6r), stem cell factor (scf), fibroblast growth factor (fgf), leukaemia inhibitory factor (lif), interleukin 11 (ii-11), oncostatin and cardiotrophin; b) seeding the suspension of es cells obtained in step a) on a layer of feeder cells and further culturing the es cells for at least between 2 to 10 passages; c) optionally removing at least one growth factors selected scf, fgf, ii-6, ii-6r, lif, oncostatin and cardiotrophin and ii-11 from the culture medium; d) further culturing the es cells in the medium of step c) on a layer of feeder cells.. .
Valneva


08/13/15
20150225480 

Human alpha-folate receptor chimeric antigen receptor


The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified t cell having alpha-folate receptor (fr-alpha) binding domain and cd27 costimulatory domain to treat ovarian cancer.
The Trustees Of The University Of Pennsylvania


08/13/15
20150225471 

Stabilized polypeptide insulin receptor modulators


Provided herein are stapled or stitched polypeptides comprising an alpha-helical segment, wherein the polypeptide binds to the insulin receptor, and wherein the polypeptide comprises at least two cross-linked amino acids as shown in formula (iii), or at least three cross-linked amino acids as shown in formula (iv). Further provided are pharmaceutical compositions comprising the stapled or stitched polypeptides, methods of use, e.g., methods of treating a diabetic condition or complications thereof.
President And Fellows Of Harvard College


08/13/15
20150225470 

Chimeric nk receptor and methods for treating cancer


The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a c-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif.
National Institutes Of Health (nih), U.s. Dept. Of Health And Human Services (dhhs)


08/13/15
20150225460 

Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure


What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer tx1ex2x3e where x1, x2 and x3 may be any natural or unnatural amino acid, where the peptide does not have any tnf receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.. .
Apeptico Forschung Und Entwicklung Gmbh


08/13/15
20150225432 

Compounds and compositions as tlr activity modulators


The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with toll-like receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine..
Novartis Ag


08/13/15
20150225390 

N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof


The present invention relates to compounds of general formula (i), wherein r1, lp, lq, (het)ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the gpr1 19 receptor and modulate its activity.. .
Neurocrine Biosciences, Inc.


08/13/15
20150225385 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrom, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150225381 

Imidazoline derivatives, preparation methods thereof, and their applications in medicine


Preparation methods thereof, pharmaceutical compositions comprising such derivatives, and applications of such derivatives in preparing androgen receptor antagonists and medicaments for treating diseases such as prostate cancer are described.. .

08/13/15
20150225345 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrom, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150225344 

Ethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, fragile-x syndrome, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .

08/13/15
20150225342 

Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b


Compounds that selectively negatively modulate nmda receptors containing an nr1/nr2b subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.. .
Mnemosyne Pharmaceuticals, Inc.


08/13/15
20150224289 

Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation


Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population.
Mercator Medsystems, Inc.


08/13/15
20150224190 

Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction


The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which inhibits the interaction between il-8 and at least one of its receptors for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.. .

08/13/15
20150224171 

Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment


The invention refers to a composition standardized in heterologous embryo-peptides, used as a dietary supplement and to a process for its obtainment. The composition consists of heterologous embryonic extract, standardized in embryo-peptides, maltodextrin, selenium yeast, chromium yeast, zinc chelated in embryo-peptides, pyridoxine, mixture of cationic peptides, formed by enzymatic hydrolysis of vitellus and egg white remaining after chicken embryo harvesting, with antitrypsin and endocytosis promoting activity, sodium taurocholate, expanded silicon dioxide, magnesium stearate, methylparaben and propylparaben.
Sc Hipocrate 2002 Serv Srl


08/13/15
20150224142 

Inhibition of diacylglycerol kinase to augment adoptive t cell transfer


The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (dgk) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive t cell transfer.
The Trustees Of The University Of Pennsylvania


08/13/15
20150224131 

Sirna and their use in methods and compositions for the treatment and / or prevention of eye conditions


The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (trpv).. .
Sylentis Sau


08/13/15
20150224095 

Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells


Substance p antagonists and, in particular, non-peptidic nk1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human hodgkin's lymphoma km-h2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human burkitt's lymphoma, human lung carcinoma, human ewing's sarcoma, human glioma and human osteosarcoma.. .
Antagonista Enekauno, S.l.




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2569

4934

0 - 1 - 108